CAR - t细胞治疗复发和难治性侵袭性淋巴瘤患者：来自单一放疗中心的真实世界经验

IF 3.9 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2025-08-31 DOI:10.1002/hon.70124

J.T. Jutzi, J. Wampfler, C. Ionescu, M.N. Kronig, B. Jeker, M. Hoffmann, I. Reusser, C. Haslebacher, S. Sendi Stamm, M. Schletti, B.P. Lüscher, V.U. Bacher, M. Wehrli, M. Daskalakis, T. Pabst, U. Novak

{"title":"CAR - t细胞治疗复发和难治性侵袭性淋巴瘤患者：来自单一放疗中心的真实世界经验","authors":"J.T. Jutzi, J. Wampfler, C. Ionescu, M.N. Kronig, B. Jeker, M. Hoffmann, I. Reusser, C. Haslebacher, S. Sendi Stamm, M. Schletti, B.P. Lüscher, V.U. Bacher, M. Wehrli, M. Daskalakis, T. Pabst, U. Novak","doi":"10.1002/hon.70124","DOIUrl":null,"url":null,"abstract":"<p>In this retrospective analysis on patients treated with CAR T-cells at our center, we report on the use of radiotherapy in this setting. Our real-world cohort of 90 patients with aggressive lymphomas was treated with CARs from 2019 until December 2022. We found that the outcome of a localized relapse after CARs treated with radiotherapy was comparable to patients without a relapse. With the knowledge from the collected real-world data, we should launch prospective clinical trials to further improve the use of radiotherapy, and overall the efficacy of CAR T-cell therapies for patients with aggressive lymphomas.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 5","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70124","citationCount":"0","resultStr":"{\"title\":\"CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of Radiotherapy\",\"authors\":\"J.T. Jutzi, J. Wampfler, C. Ionescu, M.N. Kronig, B. Jeker, M. Hoffmann, I. Reusser, C. Haslebacher, S. Sendi Stamm, M. Schletti, B.P. Lüscher, V.U. Bacher, M. Wehrli, M. Daskalakis, T. Pabst, U. Novak\",\"doi\":\"10.1002/hon.70124\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In this retrospective analysis on patients treated with CAR T-cells at our center, we report on the use of radiotherapy in this setting. Our real-world cohort of 90 patients with aggressive lymphomas was treated with CARs from 2019 until December 2022. We found that the outcome of a localized relapse after CARs treated with radiotherapy was comparable to patients without a relapse. With the knowledge from the collected real-world data, we should launch prospective clinical trials to further improve the use of radiotherapy, and overall the efficacy of CAR T-cell therapies for patients with aggressive lymphomas.</p>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":\"43 5\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70124\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.70124\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70124","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在本中心对CAR - t细胞治疗患者的回顾性分析中，我们报告了在这种情况下使用放疗的情况。我们在2019年至2022年12月期间对90名侵袭性淋巴瘤患者进行了car治疗。我们发现car放疗后局部复发的结果与没有复发的患者相当。根据收集到的真实世界数据，我们应该开展前瞻性临床试验，以进一步提高放疗的使用，并整体提高CAR - t细胞治疗侵袭性淋巴瘤患者的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

$CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of Radiotherapy$

查看原文本刊更多论文

CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of Radiotherapy

In this retrospective analysis on patients treated with CAR T-cells at our center, we report on the use of radiotherapy in this setting. Our real-world cohort of 90 patients with aggressive lymphomas was treated with CARs from 2019 until December 2022. We found that the outcome of a localized relapse after CARs treated with radiotherapy was comparable to patients without a relapse. With the knowledge from the collected real-world data, we should launch prospective clinical trials to further improve the use of radiotherapy, and overall the efficacy of CAR T-cell therapies for patients with aggressive lymphomas.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.